Sulfasalazine Market Generated Opportunities, Future Scope 2023-2030 | Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Dr. Reddy's Laboratories, Zydus Cadila

The global sulfasalazine market size is expected to grow from US$ 2.01 billion in 2023 to US$ 2.96 billion by 2030, at a CAGR of 5.7% during the forecast period.

Market Overview:

Sulfasalazine is an anti-inflammatory drug used mainly to treat ulcerative colitis and rheumatoid arthritis. It helps combat inflammation and reduce pain.

Market Dynamics:

The growing prevalence of inflammatory bowel disease (IBD) across the world is expected to drive the growth of the sulfasalazine market during the forecast period. According to the Crohn's & Colitis Foundation, around 1.6 million Americans have IBD, which includes ulcerative colitis and Crohn's disease. Sulfasalazine is one of the preferred treatment options for patients suffering from mild to moderate IBD. Additionally, increasing strategic collaborations between manufacturers is also projected support the market growth between 2023 and 2030. For instance, in August 2021, Innovus Pharmaceuticals, Inc. announced a strategic collaboration and license agreement with NTC Pharma Limited to commercialize Enteragam, an over-the-counter probiotic and prebiotic formulation in the United States and Canada.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/6138

Market Trend:

A key trend being witnessed in the global sulfasalazine market is the rising preference for self-administrable drug formats and home healthcare models. The ongoing Covid-19 pandemic has further prioritized the development of patient-friendly formulations that need minimal clinical supervision. This is due to the incentives of avoiding frequent hospital visits and reducing health infrastructure burden. In line with this, manufacturers are focusing on easy-to-use formulations like oral suspensions, melt-away tablets and once-daily dosage strengths of sulfasalazine to promote self-administration at home. Furthermore, the incorporation of digital technologies enables remote monitoring of treatment adherence and outcomes. The transition towards self-care and home-based management models is expected to considerably drive the market demand for convenient sulfasalazine delivery platforms during the forecast period.

Competitive Landscape

In the segment specifically devoted to leading companies in the Sulfasalazine Market of the market analysis document, our researchers provide a summary of the financial statements of all the major companies, covering their noteworthy developments, product benchmarking, and SWOT analysis. The corporate profile copy also includes financial information and a business summary. The businesses in this area can be customized to match the unique needs of the client.

Some of the Top Players in Sulfasalazine Market:

Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Dr. Reddy's Laboratories, Zydus Cadila, Sun Pharmaceutical Industries, Aspen Pharmacare, Apotex Inc., Sandoz (a division of Novartis), Lupin Limited

Detailed Segmentation:

Global Sulfasalazine Market, Product Type:
Generic Sulfasalazine
Branded Sulfasalazine

Global Sulfasalazine Market, Application:
Rheumatoid Arthritis
Inflammatory Bowel Diseases
Crohn's Disease
Ulcerative Colitis

Global Sulfasalazine Market, Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics

Global Sulfasalazine Market, Patient Demographics:
Adults
Pediatrics

Global Sulfasalazine Market, Disease Severity:
Mild
Moderate
Severe

Global Sulfasalazine Market, Prescription Type:
Over-the-Counter (OTC) with medical supervision
Prescription-only

Global Sulfasalazine Market, End User:
Hospitals
Clinics
Ambulatory Surgical Centers
Homecare

Global Sulfasalazine Market, Patient Education and Support:
Patient Support Programs
Educational Material
Healthcare Professional Training

Regional Analysis -

North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
Latin America (Colombia, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now and Get a Discount on this Report @ https://www.coherentmarketinsights.com/insight/buy-now/6138

Market Driver:

While sulfasalazine remains a commonly used treatment option for mild to moderate ulcerative colitis, the past decade has witnessed a gradual shift towards biological therapies. Biologics offer a safer and more targeted treatment approach with lesser side effects as compared to conventional medications like sulfasalazine. They work by specifically blocking certain components of the body's immune system that cause ulcerative colitis. Drugs in the biologics category include infliximab, adalimumab, golimumab and vedolizumab. With increasing availability and affordability, biologics are rapidly becoming the preferred choice for managing moderate to severe cases of ulcerative colitis. The rising popularity of these advanced treatment options can hinder the growth prospects of conventional drugs including sulfasalazine in the coming years.

Market Restraint:

Most of the major sulfasalazine brands available in the global market are expected to lose their patent protection by 2023-2024. Once the patents expire, multiple generic drug manufacturers are likely to introduce low-cost biosimilar versions of popular sulfasalazine brands. This will considerably bring down the overall prices of sulfasalazine medications. The entry of affordable generic versions after patent expiry is predicted to boost the treatment uptake and widen the consumer base of sulfasalazine globally. The growing access and affordability owing to imminent patent expiry will present lucrative opportunities for players in the sulfasalazine market.

Market Opportunity:

Over the years, considerable research efforts have been directed towards developing novel site-specific and targeted delivery systems for sulfasalazine to maximize its therapeutic potential. Some of the actively explored approaches include enteric-coated formulations, multidrug polymers, conjugate prodrugs and nanoparticles. These innovative platforms are aimed at protecting sulfasalazine from degradation in the stomach, facilitating its controlled release at the inflamed colonic regions and reducing systemic absorption and toxicity. Going forward, the approval and commercialization of advanced delivery technologies that enhance the bioavailability, safety and efficiency of sulfasalazine will present attractive opportunities in the market. Their introduction may aid in expanding the eligible patient population and indications for sulfasalazine therapy.

Reasons to Purchase this Report:

✔ Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
✔ Reports provide opportunities and threats faced by suppliers in the Sulfasalazine industry around the world.
✔ The report shows regions and sectors with the fastest growth potential.
✔A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
✔ The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
✔ This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/6138

Questions Answered by the Report:

(1) Which are the dominant players of the Sulfasalazine Market?
(2) What will be the size of the Sulfasalazine Market in the coming years?
(3) Which segment will lead the Sulfasalazine Market?
(4) How will the market development trends change in the next five years?
(5) What is the nature of the competitive landscape of the Sulfasalazine Market?
(6) What are the go-to strategies adopted in the Sulfasalazine Market?

Table of Contents

Chapter 1 Market Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Market Size Analysis from 2023 to 2030

Chapter 2 Competition by Types, Applications, and Top Regions and Countries
2.1 Market (Volume and Value) by Type
2.3 Market (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Worldwide Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Sulfasalazine Sales, Consumption, Export, Import by Regions (2023-2023)
Chapter 5 North America Market Analysis
Chapter 6 Europe Market Analysis
Chapter 7 Middle East and Africa Market Analysis
Chapter 8 Asia Pacific Market Analysis
Chapter 9 Latin America Market Analysis
Chapter 10 Company Profiles and Key Figures in Sulfasalazine Business
Chapter 11 Market Forecast (2023-2030)
Chapter 12 Conclusions

📌Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
📞U.K.: +44-020-8133-4027
📞JAPAN: +81-50-5539-1737
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.